PRODUCT INFORMATION

BAY-3827

Item No. 41448



CAS Registry No.:	2377576-35-5
Formal Name:	N-[5-(3,5-dicyano-1,4-dihydro-1,2,6-trimethyl-4-pyridinyl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethyl-benzamide
MF:	$C_{27}H_{25}FN_6O$
FW:	468.5
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY-3827 is supplied as a solid. A stock solution may be made by dissolving the BAY-3827 in the solvent of choice, which should be purged with an inert gas. BAY-3827 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

BAY-3827 is an inhibitor of AMP-activated protein kinase (AMPK; IC_{50} = 1.4 nM at 10 µM ATP).[1] It is selective for AMPK over Aurora A kinase, FMS-related tyrosine kinase 3 (FLT3), and c-Met (IC_{50}s = 1,324, 124, and 788 nM, respectively), p90 ribosomal S6 kinase 2 (RSK2), RSK3, RSK4, p90 ribosomal S6 kinase 1 (MSK1), and MST3 (IC_{50}s = 52, 36, 24, 43, and 94 nM, respectively), and a panel of 331 kinases at 10 µM but does inhibit RSK1 (IC_{50} = 9 nM). BAY-3827 selectively inhibits the proliferation of androgen-dependent LNCaP, VCaP, and 22Rv1 prostate cancer cells (IC_{50}s = 0.28, 1.71, and 5.55 µM, respectively) over androgen receptor-negative C4-2B, PC3, and DU145 prostate cancer cells (IC_{50}s = >10 µM for all).

Reference

1. Lemos, C., Schulze, V.K., Baumgart, S.J., *et al.* The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. *Cell. Oncol. (Dordr)* **44(3)**, 581-594 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM